Monte Rosa Therapeutics, Inc. - GLUE
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | Vestal Point Capital, LP | 5.4% | 4,600,000 | View |
| Aug 14, 2026 | SCHEDULE 13G | Ryan Wilder | 5.4% | 4,600,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Montanova Capital, LLC | 4.2% | 3,549,539 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Averill Master Fund, Ltd. | 3.8% | 3,215,486 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Aaron Cowen | 4.2% | 3,549,539 | View |
| Jul 08, 2026 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 10.5% | 8,861,282 | View |
| Jul 06, 2026 | SCHEDULE 13D/A | — | 5.0% | — | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover GP II, LLC | 2.7% | 2,311,076 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover Fund II, L.P. | 2.7% | 2,311,076 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover GP III, LLC | 2.7% | 2,311,075 | View |
| May 15, 2026 | SCHEDULE 13G/A | TCG Crossover Fund III, L.P. | 2.7% | 2,311,075 | View |
| May 15, 2026 | SCHEDULE 13G/A | Chen Yu | 5.5% | 4,622,151 | View |
| May 15, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors LP | 9.99% | 8,876,346 | View |
| May 15, 2026 | SCHEDULE 13G/A | Baker Bros. Advisors (GP) LLC | 9.99% | 8,876,346 | View |
| May 15, 2026 | SCHEDULE 13G/A | Julian C. Baker | 9.99% | 8,876,346 | View |
| May 15, 2026 | SCHEDULE 13G/A | Felix J. Baker | 9.99% | 8,876,346 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 3.4% | 2,716,569 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 3.4% | 2,716,569 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.5% | 1,986,984 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.5% | 1,986,984 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 306,361 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 306,361 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 5.8% | 4,703,553 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 6.3% | 5,085,886 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 6.3% | 5,085,886 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 6.3% | 5,085,886 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Adam Goulburn | 8.1% | 6,513,765 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Zavain Dar | 8.1% | 6,513,765 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Nan Li | 8.1% | 6,513,765 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Management, L.P. | 8.1% | 6,513,765 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Capital I GP, LLC | 7.1% | 5,663,265 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Management GP, LLC | 8.1% | 6,513,765 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Capital I, L.P. | 7.1% | 5,663,265 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Capital II, L.P. | 1.1% | 850,500 | View |
| Apr 22, 2026 | SCHEDULE 13G/A | Dimension Capital II GP, LLC | 1.1% | 850,500 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.